Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CTEC: Cholestech any other investors? -- Ignore unavailable to you. Want to Upgrade?

To: Duane L. Olson who wrote (682)	8/18/1999 9:45:00 AM
From: Lane3	Read Replies (1) \| Respond to of 710

TSO, you're relentless! Did you ever sell cars for a living? Here's another notch of movement on the pessimism-o-meter. ----- August 18, 4:00 am Eastern Time Company Press Release Cholestech L.D.X System Chosen for Parke-Davis' 1999 Disease Management Initiative at CVS Drug Stores HAYWARD, Calif.--(BW HealthWire)--Aug. 17, 1999--Cholestech Corporation (Nasdaq:CTEC - news) announced today that the Cholestech L.D.X© System has been selected by Parke-Davis, a division of Warner-Lambert Company, and Pfizer as part of a nationwide cholesterol screening and education initiative. Preventive care testing for ongoing lipid management of hyperlipidemia is now available at select retail CVS pharmacies as part of a pilot program in pharmacy based intervention and disease management. ``We are excited by this opportunity to partner with Parke-Davis, Pfizer and Cholestech, as we expand our Pharmacy Care Services,' said Chris Bodine, senior vice president of Health Care Services of CVS. ``CVS is committed to providing programs of patient care and effective disease management, which support the needs of our customers.' Parke-Davis, Pfizer has provided an educational grant to support cholesterol screening and education in participating pharmacies, including lipid management education, patient education concerning the risks of hyperlipidemia, and pharmacist support programs to test and counsel patients. ``We began our pilot program with CVS and Parke-Davis in January to assist the public in determining their potential risk of coronary heart disease, the number one killer of Americans,' said Warren E. Pinckert II, president and CEO of Cholestech. ``Cholestech has been proud to be a part of Parke-Davis' many programs to educate consumers on the risks of high cholesterol and the steps Americans can take to reach their target lipid levels and control this potentially life-threatening disease. Our pharmacy partner, CVS, has been able to establish a leadership position in pharmacy-based disease management through this pilot and other customer care programs.'